{"protocolSection":{"identificationModule":{"nctId":"NCT03839355","orgStudyIdInfo":{"id":"17-010544"},"organization":{"fullName":"Mayo Clinic","class":"OTHER"},"briefTitle":"Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation","officialTitle":"Randomized Trial of Apixaban vs Dose Adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients With CHA2DS2-VaSc Score = 2","acronym":"ARISTA"},"statusModule":{"statusVerifiedDate":"2021-02","overallStatus":"TERMINATED","whyStopped":"Study terminated due to slower than anticipated enrollment.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-12-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-12-15","type":"ACTUAL"},"completionDateStruct":{"date":"2020-12-15","type":"ACTUAL"},"studyFirstSubmitDate":"2019-02-11","studyFirstSubmitQcDate":"2019-02-13","studyFirstPostDateStruct":{"date":"2019-02-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-02-05","resultsFirstSubmitQcDate":"2021-02-23","resultsFirstPostDateStruct":{"date":"2021-03-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-02-23","lastUpdatePostDateStruct":{"date":"2021-03-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Malini Madhavan","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Mayo Clinic"},"leadSponsor":{"name":"Mayo Clinic","class":"OTHER"},"collaborators":[{"name":"Pfizer","class":"INDUSTRY"},{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin. The investigators also hypothesize that Apixaban reduces cognitive decline by reducing the rate of new cerebral infarction and cerebral microbleeds detected by cerebral MRI compared to warfarin."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Apixaban","Warfarin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":34,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Eliquis","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Apixaban"]},{"label":"Warfarin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Warfarin"]}],"interventions":[{"type":"DRUG","name":"Apixaban","description":"Dosage either 5mg or 2.5mg for 2 years","armGroupLabels":["Eliquis"],"otherNames":["Eliquis"]},{"type":"DRUG","name":"Warfarin","description":"Dosage assessed by your treating physician for 2 years","armGroupLabels":["Warfarin"],"otherNames":["Coumadin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Standardized Neurocognitive Function Score","description":"Assess the change in cognitive function using standardized neurocognitive assessment.","timeFrame":"Baseline, Year 1, Year 2"},{"measure":"MRI Evidence of Silent Cerebral Infarct","description":"Magnetic Resonance Imagining of the brain to assess the development of new silent cerebral infarcts.","timeFrame":"Baseline, Year 2"},{"measure":"MRI Evidence of New Cerebral Micro-bleeds","description":"Magnetic Resonance Imagining of the brain to assess the development of new cerebral micro-bleeds","timeFrame":"Baseline, Year 2"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-valvular Atrial Fibrillation\n* CHA2DS2-VASc Score \\> or = to 2\n* Never been treated with Apixaban (Eliquis) or prior treatment of \\< 1 month\n* Candidate for oral anticoagulation as assessed by a treating physician\n\nExclusion Criteria:\n\n* Valvular Atrial Fibrillation (Rheumatic valve disease,Moderate or greater mitral stenosis,Mechanical cardiac valve)\n* Active Bleeding\n* Prior treatment with Apixaban \\>1 month\n* Recent stroke within 7 days\n* Dementia\n* Implanted devices not compatible with MRI/any cardiac implanted device\n* Claustrophobia\n* Active alcohol/drug abuse\n* Life expectancy \\< 1 year\n* Taking asprin with \\>100mg doses\n* Known hypersensitivity to warfarin or Apixaban\n* Severe renal insufficiency\n* Prior severe bleeding (Intracranial bleeding (subdural, subarachnoid, intraparenchymal bleeding),GI bleed requiring transfusion,Bleeding from other sites requiring transfusion)\n* Psychosocial reasons that make study participation impractical\n* Currently enrolled in another IND or IDE trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints\n* Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or that could impact the scientific integrity of the study.\n* Prisoners or subjects who are involuntarily incarcerated\n* Subjects who are compulsorily detained for treatment of either psychiatric or physical illness\n* Current or expected systemic treatment with strong dual inhibitors of CYP3A4 and P-gp (Any one of rifampin, carbamazepine, phenytoin, St. John's Wort, ketoconazole, itraconazole, ritonavir, clarithromycin)\n* Need for dual anti-platelet therapy with aspirin and another agent such as thienopyridine","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Malini Madhavan","affiliation":"Mayo Clinic","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Mayo Clinic in Rochester","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Mayo Clinic Clinical Trials","url":"https://www.mayo.edu/research/clinical-trials"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Eliquis","description":"Apixaban: Dosage either 5mg or 2.5mg for 2 years"},{"id":"FG001","title":"Warfarin","description":"Warfarin: Dosage assessed by your treating physician for 2 years"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Eliquis","description":"Apixaban: Dosage either 5mg or 2.5mg for 2 years"},{"id":"BG001","title":"Warfarin","description":"Warfarin: Dosage assessed by your treating physician for 2 years"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"34"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"77.4","spread":"5.84"},{"groupId":"BG001","value":"76.4","spread":"5.61"},{"groupId":"BG002","value":"76.9","spread":"5.72"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"34"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"18"}]}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"34"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Standardized Neurocognitive Function Score","description":"Assess the change in cognitive function using standardized neurocognitive assessment.","populationDescription":"Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, Year 1, Year 2","groups":[{"id":"OG000","title":"Eliquis","description":"Apixaban: Dosage either 5mg or 2.5mg for 2 years"},{"id":"OG001","title":"Warfarin","description":"Warfarin: Dosage assessed by your treating physician for 2 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"PRIMARY","title":"MRI Evidence of Silent Cerebral Infarct","description":"Magnetic Resonance Imagining of the brain to assess the development of new silent cerebral infarcts.","populationDescription":"Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, Year 2","groups":[{"id":"OG000","title":"Eliquis","description":"Apixaban: Dosage either 5mg or 2.5mg for 2 years"},{"id":"OG001","title":"Warfarin","description":"Warfarin: Dosage assessed by your treating physician for 2 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"PRIMARY","title":"MRI Evidence of New Cerebral Micro-bleeds","description":"Magnetic Resonance Imagining of the brain to assess the development of new cerebral micro-bleeds","populationDescription":"Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, Year 2","groups":[{"id":"OG000","title":"Eliquis","description":"Apixaban: Dosage either 5mg or 2.5mg for 2 years"},{"id":"OG001","title":"Warfarin","description":"Warfarin: Dosage assessed by your treating physician for 2 years"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse events were collected from baseline to end of treatment for approximately 24 months.","eventGroups":[{"id":"EG000","title":"Eliquis","description":"Apixaban: Dosage either 5mg or 2.5mg for 2 years","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":0,"otherNumAtRisk":18},{"id":"EG001","title":"Warfarin","description":"Warfarin: Dosage assessed by your treating physician for 2 years","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":0,"otherNumAtRisk":16}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Malini Madhavan","organization":"Mayo Clinic","email":"Madhavan.Malini@mayo.edu","phone":"507-255-4152"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-12-18","uploadDate":"2021-01-12T09:41","filename":"Prot_SAP_000.pdf","size":805165}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2021-02-24","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000007238","term":"Infarction"},{"id":"D000007511","term":"Ischemia"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020521","term":"Stroke"},{"id":"D000014652","term":"Vascular Diseases"}],"browseLeaves":[{"id":"M29395","name":"Cognitive Dysfunction","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarct","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC10","name":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014859","term":"Warfarin"},{"id":"C000522181","term":"Apixaban"}],"ancestors":[{"id":"D000000925","term":"Anticoagulants"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M288142","name":"Apixaban","asFound":"Extraction","relevance":"HIGH"},{"id":"M17292","name":"Warfarin","asFound":"Third","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":true}